SCHEMBL3847008

SCHEMBL3847008

Cc1c(I)cccc1CNc1nc(Cl)ncc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 15/20 0.51
PIN1 Q13526 5/20 0.49
CYP3A4 P08684 4/20 0.43
CYP2C9 P11712 4/20 0.43
CYP2D6 P10635 3/20 0.43
MAP4K4 O95819 2/20 0.43
CDK1 P06493 2/20 0.43
PIM1 P11309 2/20 0.43
CDK2 P24941 2/20 0.43
CSNK1D P48730 2/20 0.43
CLK2 P49760 2/20 0.43
GSK3A P49840 2/20 0.43
GSK3B P49841 2/20 0.43
IRAK1 P51617 2/20 0.43
RPS6KA3 P51812 2/20 0.43
CDK5 Q00535 2/20 0.43
PRKCD Q05655 2/20 0.43
PRKAA1 Q13131 2/20 0.43
STK3 Q13188 2/20 0.43
CAMK2B Q13554 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274362 0.78 PIN1 (0.58) PRKCQPIN1CYP3A4CYP2C9CYP2D6
SCHEMBL14217804 0.78 PIN1 (0.48) PRKCQPIN1CYP3A4CYP2C9CYP2D6
SCHEMBL16793205 0.77 PRKCQ (0.59) PRKCQPIN1CYP3A4CYP2C9CYP2D6
SCHEMBL3854087 0.77 PRKCQ (0.54) PRKCQPIN1
SCHEMBL3971786 0.76 PIN1 (0.65) PRKCQPIN1
SCHEMBL6193447 0.76 PRKCQ (0.53) PRKCQPIN1CYP3A4CYP2C9CYP2D6
SCHEMBL3847319 0.75 PRKCQ (0.60) PRKCQPIN1CYP3A4CYP2C9CYP2D6
SCHEMBL1266942 0.75 PRKCQ (0.57) PRKCQPIN1
SCHEMBL1804900 0.74 PIN1 (0.57) PRKCQPIN1
SCHEMBL1917607 0.73 PIN1 (0.57) PRKCQPIN1CYP3A4CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2009-11-12 US disclosed
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2009-11-12 US disclosed
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2009-11-12 US disclosed
WO-2009062059-A2 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2009-05-14 WO disclosed
WO-2009062059-A2 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2009-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281075-A1 ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PRKCE, PRKCZ, PRKCQ PRKCQ 3/4885PIN1 967/4885CYP3A4 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.